This proof of concept demonstrates stable, multivalent immunoreagents in DIVA diagnostics, suggesting a new adaptable framework.
Serological diagnostics rely on antigens that are stable, specific, and manufacturable at scale. Full-length viral glycoproteins often fail to meet these criteria due to instability, low expression, or cross-reactivity. Here, we present a modular antigen-display platform that combines rational epitope selection with self-assembling ring-like particles (RLPs) to generate multivalent, solvent-exposed immunoreagents. As a proof of concept, we applied this strategy to glycoprotein E (gE) of Suid herpesvirus 1 (SuHV-1), a key target in DIVA (Differentiating Infected from Vaccinated Animals) diagnostics. Three immunodominant gE regions were identified using IEDB curation and BepiPred-3.0 prediction and grafted onto RLPs to produce a stable ∼18 nm multiepitope construct (RLP-Epi). RLP-Epi assembled homogeneously, remained stable during storage, and was specifically recognized by a commercial anti-gE monoclonal antibody. The construct exhibited reliable performance in both indirect and blocking ELISA formats, with ROC analysis demonstrating high sensitivity and specificity in both configurations. Vaccinated-only sera showed no reactivity against RLP-Epi, confirming DIVA compatibility. These results demonstrate that RLP-based epitope engineering offers a generalizable framework for designing stable, modular diagnostic antigens suitable for rapid adaptation to emerging variants.
No takes yet. Share an insight, caveat, or question.
Goldin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: